Works by WINDYGA, J.

Results: 31

Practical aspects of factor concentrate use in patients with von Willebrand disease undergoing invasive procedures: a European survey.

Published in:

Haemophilia, 2016, v. 22, n. 5, p. 739, doi. 10.1111/hae.12955

By:

Windyga, J.;
Dolan, G.;
Altisent, C.;
Katsarou, O.;
López Fernández, M. ‐ F.;
Zülfikar, B.

Publication type:

Article

Activated prothrombin complex concentrate in combination with tranexamic acid: a single centre experience for the treatment of mucosal bleeding and dental extraction in haemophilia patients with inhibitors.

Published in:

Haemophilia, 2016, v. 22, n. 5, p. e465, doi. 10.1111/hae.13035

By:

Windyga, J.;
Stefanska ‐ Windyga, E.;
Odnoczko, E.;
Baran, B.;
Czubak, G.

Publication type:

Article

Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme.

Published in:

Haemophilia, 2016, v. 22, n. 3, p. 349, doi. 10.1111/hae.12839

By:

Oldenburg, J.;
Windyga, J.;
Hampton, K.;
Lalezari, S.;
Tseneklidou‐Stoeter, D.;
Beckmann, H.;
Maas Enriquez, M.

Publication type:

Article

Practical aspects of DDAVP use in patients with von Willebrand Disease undergoing invasive procedures: a European survey.

Published in:

Haemophilia, 2016, v. 22, n. 1, p. 110, doi. 10.1111/hae.12763

By:

Windyga, J.;
Dolan, G.;
Altisent, C.;
Katsarou, O.;
López Fernández, M.‐F.;
Zülfikar, B.

Publication type:

Article

Total elbow arthroplasty in patient with severe von Willebrand disease.

Published in:

Haemophilia, 2014, v. 20, n. 6, p. e441, doi. 10.1111/hae.12555

By:

KOTELA, I.;
ZBIKOWSKI, P.;
AMBROZIAK, P.;
BUCZMA, A.;
GWOZDOWSKA, A.;
KOTELA, A.;
WINDYGA, J .

Publication type:

Article

Efficacy and safety of a recombinant factor IX (Bax326)a in previously treated patients with severe or moderately severe haemophilia B undergoing surgical or other invasive procedures: a prospective, open-label, uncontrolled, multicentre, phase III study.

Published in:

Haemophilia, 2014, v. 20, n. 5, p. 651, doi. 10.1111/hae.12419

By:

WINDYGA, J.;
LISSITCHKOV, T.;
STASYSHYN, O.;
MAMONOV, V.;
GHANDEHARI, H.;
CHAPMAN, M.;
FRITSCH, S.;
WONG, W.-Y.;
PAVLOVA, B. G.;
ABBUEHL, B. E.

Publication type:

Article

Improvement in health-related quality of life with recombinant factor IX prophylaxis in severe or moderately severe haemophilia B patients: results from the BAX326 Pivotal Study.

Published in:

Haemophilia, 2014, v. 20, n. 3, p. 362, doi. 10.1111/hae.12315

By:

Windyga, J.;
Lin, V. W.;
Epstein, J. D.;
Ito, D.;
Xiong, Y.;
Abbuehl, B. E.;
Ramirez, J. H.

Publication type:

Article

Correlation between endogenous VWF:Ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII- FS.

Published in:

Haemophilia, 2014, v. 20, n. 1, p. e15, doi. 10.1111/hae.12294

By:

Lalezari, S.;
Martinowitz, U.;
Windyga, J.;
Enriquez, M. M.;
Delesen, H.;
Schwartz, L.;
Scharrer, I.

Publication type:

Article

Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level ≤2%) haemophilia B.

Published in:

Haemophilia, 2014, v. 20, n. 1, p. 15, doi. 10.1111/hae.12228

By:

Windyga, J.;
Lissitchkov, T.;
Stasyshyn, O.;
Mamonov, V.;
Rusen, L.;
Lamas, J. L.;
Oh, M.‐S.;
Chapman, M.;
Fritsch, S.;
Pavlova, B. G.;
Wong, W.‐Y.;
Abbuehl, B. E.

Publication type:

Article

Health-related quality of life in patients with haemophilia and inhibitors on prophylaxis with anti-inhibitor complex concentrate: results from the Pro- FEIBA study.

Published in:

Haemophilia, 2013, v. 19, n. 5, p. 736, doi. 10.1111/hae.12178

By:

Gringeri, A.;
Leissinger, C.;
Cortesi, P. A.;
Jo, H.;
Fusco, F.;
Riva, S.;
Antmen, B.;
Berntorp, E.;
Biasoli, C.;
Carpenter, S.;
Kavakli, K.;
Morfini, M.;
Négrier, C.;
Rocino, A.;
Schramm, W.;
Windyga, J.;
Zülfikar, B.;
Mantovani, L. G.

Publication type:

Article

Management of factor VII-deficient patients undergoing joint surgeries - preliminary results of locally developed treatment regimen.

Published in:

Haemophilia, 2013, v. 19, n. 1, p. 89, doi. 10.1111/j.1365-2516.2012.02921.x

By:

Windyga, J.;
Zbikowski, P.;
Ambroziak, P.;
Baran, B.;
Kotela, I.;
Stefanska‐Windyga, E.

Publication type:

Article

von Willebrand's disease: a report from a meeting in the Åland islands.

Published in:

Haemophilia, 2012, v. 18, p. 1, doi. 10.1111/j.1365-2516.2012.02925.x

By:

Berntorp, E.;
Peake, I.;
Budde, U.;
Laffan, M.;
Montgomery, R.;
Windyga, J.;
Goodeve, A.;
Petrini, P.;
Depka, M.;
Miesbach, W.;
Lillicrap, D.;
Federici, A. B.;
Lassila, R.;
White, G.

Publication type:

Article

Short and long-term management of haemophilia A patient requiring heart valve surgery.

Published in:

Haemophilia, 2012, v. 18, n. 4, p. e352, doi. 10.1111/j.1365-2516.2012.02812.x

By:

ZATORSKA, K.;
ORŁOWSKA-BARANOWSKA, E.;
ABRAMCZUK, E.;
KUŚMIERCZYK, M.;
GRESZATA, L.;
GRABOWSKI, M.;
STĘPIŃSKA, J.;
BARAN, B.;
WINDYGA, J.

Publication type:

Article

Recommendations for assessment, monitoring and follow-up of patients with haemophilia.

Published in:

Haemophilia, 2012, v. 18, n. 3, p. 319, doi. 10.1111/j.1365-2516.2011.02671.x

By:

DE MOERLOOSE, P.;
FISCHER, K.;
LAMBERT, T.;
WINDYGA, J.;
BATOROVA, A.;
LAVIGNE-LISSALDE, G.;
ROCINO, A.;
ASTERMARK, J.;
HERMANS, C.

Publication type:

Article

An ultrapure plasma-derived monoclonal antibody-purified factor IX concentrate (Nonafact.

Published in:

Haemophilia, 2011, v. 17, n. 3, p. 439, doi. 10.1111/j.1365-2516.2010.02453.x

By:

Mauser-Bunschoten, E. P.;
Kleine Budde, I.;
Lopaciuk, S.;
Koopman, M. M. W.;
Van Der Meer, F. J. M.;
NOVÀkovÀ, I. R. O.;
Ypma, P.;
Van Der Linden, P. W. G.;
Windyga, J.;
Strengers, P. F. W.

Publication type:

Article

Registry of inherited bleeding disorders in Poland - current status and potential role of the HemoRec database.

Published in:

Haemophilia, 2011, v. 17, n. 1, p. e189, doi. 10.1111/j.1365-2516.2010.02371.x

By:

ZDZIARSKA, J.;
CHOJNOWSKI, K.;
KLUKOWSKA, A.;
ŁĘTOWSKA, M.;
MITAL, A.;
MUSIAŁ, J.;
PODOLAK-DAWIDZIAK, M.;
WINDYGA, J.;
OVESNA, P.;
BRABEC, P.;
ZAWILSKA, K.

Publication type:

Article

Non-genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report.

Published in:

Haemophilia, 2010, v. 16, n. 5, p. 747, doi. 10.1111/j.1365-2516.2010.02231.x

By:

ASTERMARK, J.;
ALTISENT, C.;
BATOROVA, A.;
DINIZ, M. J.;
GRINGERI, A.;
HOLME, P. A.;
KARAFOULIDOU, A.;
LOPEZ-FERNÁNDEZ, M. F.;
REIPERT, B. M.;
ROCINO, A.;
SCHIAVONI, M.;
von DEPKA, M.;
WINDYGA, J.;
FIJNVANDRAAT, K.

Publication type:

Article

BDDrFVIII (Moroctocog alfa [AF-CC]) for surgical haemostasis in patients with haemophilia A: results of a pivotal study.

Published in:

Haemophilia, 2010, v. 16, n. 5, p. 731, doi. 10.1111/j.1365-2516.2010.02239.x

By:

WINDYGA, J.;
RUSEN, L.;
GRUPPO, R.;
O’BRIEN, A. C.;
KELLY, P.;
ROTH, D. A;
ARKIN, S.

Publication type:

Article

Modulation of factor VIII-specific memory B cells.

Published in:

Haemophilia, 2010, v. 16, n. 102, p. 25, doi. 10.1111/j.1365-2516.2008.01962.x

By:

REIPERT, B. M.;
ALLACHER, P.;
HAUSL, C.;
PORDES, A. G.;
AHMAD, R. U.;
LANG, I.;
ILAS, J.;
WINDYGA, J.;
KLUKOWSKA, A.;
MUCHITSCH, E. M.;
SCHWARZ, H. P.

Publication type:

Article

European curriculum for thrombosis and haemostasis.

Published in:

Haemophilia, 2009, v. 15, n. 1, p. 337, doi. 10.1111/j.1365-2516.2008.01836.x

By:

ASTERMARK, J.;
NEGRIER, C.;
HERMANS, C.;
HOLME, P. A.;
KLAMROTH, R.;
KOTSI, P.;
DE MOERLOOSE, P.;
PASI, J.;
ROCINO, A.;
VON DEPKA, M.;
WINDYGA, J.;
LUDLAM, C. A.

Publication type:

Article

Treatment and prevention of acute bleedings in von Willebrand disease – efficacy and safety of Wilate®, a new generation von Willebrand factor/factor VIII concentrate.

Published in:

Haemophilia, 2009, v. 15, n. 1, p. 122, doi. 10.1111/j.1365-2516.2008.01901.x

By:

BERNTORP, E.;
WINDYGA, J.

Publication type:

Article

Phenotype – genotype correlation in eight Polish patients with inherited Factor XIII deficiency: identification of three novel mutations.

Published in:

Haemophilia, 2007, v. 13, n. 5, p. 649, doi. 10.1111/j.1365-2516.2007.01517.x

By:

IVASKEVICIUS, V.;
WINDYGA, J.;
BARAN, B.;
SCHROEDER, V.;
JUNEN, J.;
BYKOWSKA, K.;
SEIFRIED, E.;
KOHLER, H. P.;
OLDENBURG, J.

Publication type:

Article

Current use of by-passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitors.

Published in:

Haemophilia, 2007, v. 13, n. 1, p. 38, doi. 10.1111/j.1365-2516.2006.01403.x

By:

ASTERMARK, J.;
ROCINO, A.;
VON DEPKA, M.;
VAN DEN BERG, H. M.;
GRINGERI, A.;
MANTOVANI, L. G.;
MORADO, M.;
GARRIDO, R. P.;
SCHIAVONI, M.;
VILLAR, A.;
WINDYGA, J.

Publication type:

Article

Preliminary results of HBV DNA testing of Polish haemophilia patients – lack of occult HBV infection.

Published in:

Haemophilia, 2006, v. 12, n. 4, p. 380, doi. 10.1111/j.1365-2516.2006.01293.x

By:

Windyga, J.;
Brojer, E.;
Gronowska, A.;
Grabarcyzk, P.;
Mikulska, K.;
Szczepanik, A. B.;
Stefańska, E.;
Buczma, A.

Publication type:

Article

Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors.

Published in:

Haemophilia, 2006, v. 12, n. 4, p. 363, doi. 10.1111/j.1365-2516.2006.01296.x

By:

Astermark, J.;
Morado, M.;
Rocino, A.;
Van Den Berg, H. M.;
Von Depka, M.;
Gringeri, A.;
Mantovani, L.;
Garrido, R. P.;
Schiavoni, M.;
Villar, A.;
Windyga, J.

Publication type:

Article

Haemophilia in Poland.

Published in:

Haemophilia, 2006, v. 12, n. 1, p. 52, doi. 10.1111/j.1365-2516.2006.01188.x

By:

Windyga, J.;
Lopaciuk, S.;
Stefanska, E.;
Juszynski, A.;
Wozniak, D.;
Strzelecki, O.;
Szczepanik, A. B.

Publication type:

Article

Helicobacter pylori infection in patients with haemophilia in Poland: prevalence and risk of upper gastrointestinal bleeding.

Published in:

Haemophilia, 2005, v. 11, n. 4, p. 376, doi. 10.1111/j.1365-2516.2005.01086.x

By:

Szczepanik, A. B.;
Zaleska, M.;
Wiszniewski, A.;
Wislawski, S.;
Misiak, A.;
Maryniak, R.;
Windyga, J.

Publication type:

Article

Clinical efficacy, safety and pharmacokinetic properties of the factor VIII concentrate Haemoctin® SDH in previously treated patients with severe haemophilia A.

Published in:

Haemophilia, 2004, v. 10, n. 5, p. 438, doi. 10.1111/j.1365-2516.2004.00947.x

By:

Wolf, D. M.;
Rokicka-Milewska, R.;
Lopaciuk, S.;
Skotnicki, A. B.;
Klukowska, A.;
Laguna, P.;
Windyga, J.;
Kotitschke, R.;
Struff, W. G.

Publication type:

Article

Individual thrombin generation and spontaneous bleeding rate during personalized prophylaxis with Nuwiq® (human‐cl rhFVIII) in previously treated patients with severe haemophilia A.

Published in:

Haemophilia, 2018, v. 24, n. 4, p. 619, doi. 10.1111/hae.13493

By:

Dargaud, Y.;
Negrier, C.;
Rusen, L.;
Windyga, J.;
Georgiev, P.;
Bichler, J.;
Solomon, C.;
Knaub, S.;
Lissitchkov, T.;
Klamroth, R.

Publication type:

Article

Fifth Åland Island conference on von Willebrand disease.

Published in:

Haemophilia, 2018, v. 24, p. 5, doi. 10.1111/hae.13475

By:

Berntorp, E.;
Ågren, A.;
Aledort, L.;
Blombäck, M.;
Cnossen, M. H.;
Croteau, S. E.;
von Depka, M.;
Federici, A. B.;
Goodeve, A.;
Goudemand, J.;
Mannucci, P. M.;
Mourik, M.;
Önundarson, P. T.;
Rodeghiero, F.;
Szántó, T.;
Windyga, J.

Publication type:

Article

PK-guided personalized prophylaxis with Nuwiq® (human-cl rh FVIII) in adults with severe haemophilia A.

Published in:

Haemophilia, 2017, v. 23, n. 5, p. 697, doi. 10.1111/hae.13251

By:

Lissitchkov, T.;
Rusen, L.;
Georgiev, P.;
Windyga, J.;
Klamroth, R.;
Gercheva, L.;
Nemes, L.;
Tiede, A.;
Bichler, J.;
Knaub, S.;
Belyanskaya, L.;
Walter, O.;
Pasi, K. J.

Publication type:

Article

Works by WINDYGA, J.

Practical aspects of factor concentrate use in patients with von Willebrand disease undergoing invasive procedures: a European survey.

Activated prothrombin complex concentrate in combination with tranexamic acid: a single centre experience for the treatment of mucosal bleeding and dental extraction in haemophilia patients with inhibitors.

Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme.

Practical aspects of DDAVP use in patients with von Willebrand Disease undergoing invasive procedures: a European survey.

Total elbow arthroplasty in patient with severe von Willebrand disease.

Efficacy and safety of a recombinant factor IX (Bax326)<sup>a</sup> in previously treated patients with severe or moderately severe haemophilia B undergoing surgical or other invasive procedures: a prospective, open-label, uncontrolled, multicentre, phase III study.

Improvement in health-related quality of life with recombinant factor IX prophylaxis in severe or moderately severe haemophilia B patients: results from the BAX326 Pivotal Study.

Correlation between endogenous VWF:Ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII- FS.

Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level ≤2%) haemophilia B.

Health-related quality of life in patients with haemophilia and inhibitors on prophylaxis with anti-inhibitor complex concentrate: results from the Pro- FEIBA study.

Management of factor VII-deficient patients undergoing joint surgeries - preliminary results of locally developed treatment regimen.

von Willebrand's disease: a report from a meeting in the Åland islands.

Short and long-term management of haemophilia A patient requiring heart valve surgery.

Recommendations for assessment, monitoring and follow-up of patients with haemophilia.

An ultrapure plasma-derived monoclonal antibody-purified factor IX concentrate (Nonafact.

Registry of inherited bleeding disorders in Poland - current status and potential role of the HemoRec database.

Non-genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report.

BDDrFVIII (Moroctocog alfa [AF-CC]) for surgical haemostasis in patients with haemophilia A: results of a pivotal study.

Modulation of factor VIII-specific memory B cells.

European curriculum for thrombosis and haemostasis.

Treatment and prevention of acute bleedings in von Willebrand disease – efficacy and safety of Wilate<sup>®</sup>, a new generation von Willebrand factor/factor VIII concentrate.

Phenotype – genotype correlation in eight Polish patients with inherited Factor XIII deficiency: identification of three novel mutations.

Current use of by-passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitors.

Preliminary results of HBV DNA testing of Polish haemophilia patients – lack of occult HBV infection.

Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors.

Haemophilia in Poland.

Helicobacter pylori infection in patients with haemophilia in Poland: prevalence and risk of upper gastrointestinal bleeding.

Clinical efficacy, safety and pharmacokinetic properties of the factor VIII concentrate Haemoctin<sup>®</sup> SDH in previously treated patients with severe haemophilia A.

Individual thrombin generation and spontaneous bleeding rate during personalized prophylaxis with Nuwiq<sup>®</sup> (human‐cl rhFVIII) in previously treated patients with severe haemophilia A.

Fifth Åland Island conference on von Willebrand disease.

PK-guided personalized prophylaxis with Nuwiq<sup>®</sup> (human-cl rh FVIII) in adults with severe haemophilia A.